Press Releases

TrialAssure® ANONYMIZE® Selected by the European Medicines Agency as Official Anonymisation Tool

TrialAssure® announced today that its ANONYMIZE® platform has been selected by the European Medicines Agency (EMA) as an official anonymisation tool used within the Agency.

CluePoints Appoints Martin Magazzolo as Chief Commercial Officer

CluePoints, provider of leading statistical and AI-driven software solutions, has appointed Martin (Marty) Magazzolo as its new Chief Commercial Officer (CCO).

ELRIG Appoints Drs Hitesh Sanganee and Marcus Schindler to Scientific Advisory Board

Leadership expansion reinforces ELRIG's commitment to delivering impactful drug discovery initiatives and driving community-wide collaboration

Acrosian Launches as AI-Era Biometrics CRO, Built by the Team Behind One of the Industry’s Largest Independent Biometrics CROs

Novo Nordisk Challenges Lilly’s GLP-1 Advertising Campaigns, Claiming Consumers Are Misled by Outdated Comparisons

Novo Nordisk has filed a lawsuit against Eli Lilly, claiming that Lilly’s GLP-1 advertising campaigns use outdated comparisons and mislead consumers about obesity and diabetes treatments. The dispute focuses on advertisements comparing Zepbound® and Mounjaro® with lower doses of Wegovy® and Ozempic®. Novo Nordisk is seeking removal of the campaigns and corrective advertising to ensure patients receive updated scientific information. The case highlights increasing competition between leading pharmaceutical companies in the fast-growing GLP-1 therapy market.

PumasAI Helps Launch India's First Computational Lab for Quantitative Sciences to Advance AI in Drug Development

New collaboration with PSGIMSR and SOPHAS strengthens education, research, and computational infrastructure for the next generation of clinical pharmacology and pharmacometrics leaders

MIB Agents Osteosarcoma Alliance Appoints Katherine Azima as Co-Director of Scientific Programs

MIB Agents Osteosarcoma Alliance, a nonprofit dedicated to Making It Better for the osteosarcoma community through research, education and patient support, today announced that Katherine Azima has joined the organization as Co-Director of Scientific Programs. In this role, Azima will work alongside Christina Ip-Toma, Co-Director of Scientific Programs, until Ip-Toma retires at the end of the year, to help lead and expand MIB Agents' growing portfolio of scientific initiatives, fostering collaboration among researchers, clinicians, industry partners and patient advocates to accelerate progress in osteosarcoma research.

Lilly to Acquire AtaiBeckley to Advance Innovative Biotech Therapies for Treatment-Resistant Depression

Eli Lilly and Company has announced a definitive agreement to acquire clinical-stage biotechnology company AtaiBeckley in a deal valued at up to $3.8 billion, including milestone-based payments. The acquisition significantly expands Lilly's neuroscience pipeline with innovative rapid-acting neuroplastogen therapies for treatment-resistant depression and other serious mental health disorders. The transaction highlights growing pharmaceutical investment in next-generation psychiatric medicines designed to deliver durable symptom relief through novel mechanisms of action.

Trajan Expands US Availability of Harpera™ Microbiopsy Punch for Clinical Skin Sampling

Trajan Scientific and Medical (Trajan), a global developer and manufacturer of analytical, life sciences, and medical technologies, has announced that its Harpera™ Microbiopsy Punch is now FDA-registered for marketing in the US. Previously available in the country for investigational use only, the suture-free device can now be used by healthcare professionals across a broader range of clinical skin sampling applications, alongside clinical research and wellness programs. The registration responds to growing demand from healthcare and research organizations for patient-friendly sampling approaches, offering a minimally invasive alternative to traditional skin biopsy that reduces collection burden while preserving sample quality for modern molecular techniques. Healthcare professionals in the US now gain expanded access to a tool that supports dermatology, biomarker research, and precision medicine, with applications spanning molecular analysis, translational research, and longitudinal skin sampling.

Sanofi Wins FDA Approval for First On-Body Injector Cancer Treatment, Making Multiple Myeloma Care Simpler

The FDA has approved Sanofi's Sarclisa Escena, making it the first anticancer therapy that can be administered through a wearable on-body injector. Clinical studies showed the new subcutaneous treatment delivers effectiveness comparable to intravenous therapy while reducing administration time and infusion-related reactions. The approval is expected to improve both patient convenience and healthcare workflow in the treatment of multiple myeloma.

Novogene Europe Launches Untargeted Metabolomics Service at Cambridge Omics Centre

• Strengthens multiomics portfolio offering metabolite-level insight to connect molecular data with biological function across broader life science studies • New workflow built around Thermo Scientific Vanquish UHPLC coupled with Orbitrap Exploris 120 high-resolution accurate-mass mass spectrometry

Novartis to Acquire Myricx Bio in USD 1.5 Billion Deal, Strengthening Next-Generation ADC Cancer Pipeline

Novartis has agreed to acquire UK-based biotech company Myricx Bio in a deal worth up to USD 1.5 billion to strengthen its oncology pipeline. The acquisition brings Myricx's next-generation NMTi antibody-drug conjugate (ADC) platform, designed to overcome resistance to existing cancer therapies. It also adds two lead ADC candidates targeting B7-H3 and HER2, expanding Novartis' portfolio for treating solid tumors. The transaction is expected to close in the second half of 2026, subject to regulatory approvals.

VisualDx Partners with Sun River Health to Expand Access to Clinical Decision Support for Underserved Patients

FDA Clears CliniComp PACS Viewer (MIMPS), Unifying Diagnostic Imaging, Enterprise EHR, and Native AI in a Single Platform

FDA Clears CliniComp PACS Viewer (MIMPS), Unifying Diagnostic Imaging, Enterprise EHR, and Native AI in a Single Platform

ProPharma Advances Technology Enablement Strategy with AI-Assisted Capability for ANDA Submission Development

New proprietary capability enhances ProPharma’s regulatory service delivery model, helping clients accelerate submission development while maintaining the highest standards of quality and compliance.

CluePoints and Tufts CSDD Publish Peer-Reviewed Evidence Quantifying the Financial Value of RBQM

New research demonstrates RBQM-enabled trials achieve up to 23x ROI and 19% shorter phase durations, providing the industry’s first quantitative business case for risk-based oversight in clinical development

Enhanced Compliance Inc. (ECI) Appoints Taranjit S. Samra as Head of Medical Device Software Engineering, Cybersecurity and AI

ECI has announced the appointment of Taranjit S. Samra, DRSc, MSEE, RAC, as Head of Medical Device Software Engineering, Cybersecurity and AI.

Siddharth Mittal Appointed as Managing Director & CEO of Syngene International

eClinical Solutions Advances Risk-Based Quality Management Solutions, Helping Sponsors Meet ICH E6(R3) Regulatory Guidelines

Enhancements further break down silos and reduce fragmentation through integrated risk and quality management within one clinical data intelligence platform

Symeres and Axxam Appoint Russell Thomas as Chief Scientific Officer to lead their collaborative integrated discovery platform